{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T10:10:12Z","timestamp":1648980612025},"reference-count":32,"publisher":"Lavoisier","issue":"4","license":[{"start":{"date-parts":[[2016,9,19]],"date-time":"2016-09-19T00:00:00Z","timestamp":1474243200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bull. Soc. Pathol. Exot."],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s13149-016-0521-2","type":"journal-article","created":{"date-parts":[[2016,9,19]],"date-time":"2016-09-19T14:11:51Z","timestamp":1474294311000},"page":"256-261","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Aper\u00e7u des vaccins Ebola en phase clinique et pr\u00e9clinique de d\u00e9veloppement"],"prefix":"10.3166","volume":"109","author":[{"given":"P.","family":"Buchy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1762","published-online":{"date-parts":[[2016,9,19]]},"reference":[{"issue":"4","key":"521_CR1","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1089\/hgtb.2015.020","volume":"26","author":"DH Amante","year":"2015","unstructured":"Amante DH, Smith TR, Mendoza JM, et al (2015) Skin Transfection Patterns and Expression Kinetics of Electroporation-Enhanced Plasmid Delivery Using the CELLECTRA-3P, a Portable Next-Generation Dermal Electroporation Device. Hum Gene Ther Methods 26(4):134\u201346","journal-title":"Hum Gene Ther Methods"},{"key":"521_CR2","doi-asserted-by":"crossref","first-page":"g7348","DOI":"10.1136\/bmj.g7348","volume":"349","author":"NJ Beeching","year":"2014","unstructured":"Beeching NJ, Fenech M, Houlihan CF (2014) Ebola virus disease. BMJ 349:g7348","journal-title":"BMJ"},{"issue":"5","key":"521_CR3","doi-asserted-by":"crossref","first-page":"1003389","DOI":"10.1371\/journal.ppat.1003389","volume":"9","author":"JE Blaney","year":"2013","unstructured":"Blaney JE, Marzi A, Willet M, et al (2013) Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine. PLoS Pathog 9(5):e1003389","journal-title":"PLoS Pathog"},{"issue":"2","key":"521_CR4","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.virol.2010.01.015","volume":"399","author":"AA Bukreyev","year":"2010","unstructured":"Bukreyev AA, Dinapoli JM, Yang L, et al (2010) Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates respiratory tract of vector-immune monkeys and is immunogenic. Virology 399(2):290\u20138","journal-title":"Virology"},{"key":"521_CR5","volume-title":"2014 Ebola Outbreak in West Africa-Case Counts","author":"Centers for Diseases ControlPrevention","year":"2016","unstructured":"Centers for Diseases Control and Prevention (2016) 2014 Ebola Outbreak in West Africa-Case Counts. [En ligne] [acc\u00e9d\u00e9 le 11 juin 2016)"},{"issue":"32","key":"521_CR6","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1016\/j.vaccine.2013.05.016","volume":"31","author":"C Deal","year":"2013","unstructured":"Deal C, Pekosz A, Ketner G (2013) Prospects for oral replicating adenovirus-vectored vaccines. Vaccine 31(32):3236\u201343","journal-title":"Vaccine"},{"issue":"17","key":"521_CR7","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1056\/NEJMoa1411627","volume":"374","author":"K1 Ewer","year":"2016","unstructured":"Ewer K1, Rampling T1, Venkatraman N, et al (2016) A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. N Engl J Med 374(17):1635\u201346","journal-title":"N Engl J Med"},{"issue":"5","key":"521_CR8","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3201\/eid0805.010284","volume":"8","author":"TW Geisbert","year":"2002","unstructured":"Geisbert TW, Pushko P, Anderson K, et al (2002) Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis 8(5):503\u20137","journal-title":"Emerg Infect Dis"},{"issue":"8","key":"521_CR9","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1128\/JVI.00074-09","volume":"83","author":"P Halfmann","year":"2009","unstructured":"Halfmann P, Ebihara H, Marzi A, et al (2009) Replicationdeficient Ebolavirus as a vaccine candidate. J Virol 83(8):3810\u20135","journal-title":"J Virol"},{"issue":"9996","key":"521_CR10","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0140-6736(15)61117-5","volume":"386","author":"AM Henao-Restrepo","year":"2015","unstructured":"Henao-Restrepo AM, Longini IM, Egger M, et al (2015) Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomized trial. Lancet 386(9996):857\u201366","journal-title":"Lancet"},{"key":"521_CR11","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.coviro.2016.03.008","volume":"17","author":"AM Henao-Restrepo","year":"2016","unstructured":"Henao-Restrepo AM, Preziosi M-P, Wood D, et al (2016) On a path to accelerate access to Ebola vaccines: The WHO\u2019s research and development efforts during the 2014-2016 Ebola epidemic in West Africa. Curr Opin Virol 17:138\u201344","journal-title":"Curr Opin Virol"},{"issue":"9","key":"521_CR12","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1128\/JVI.03361-12","volume":"87","author":"AS Herbert","year":"2013","unstructured":"Herbert AS, Kuehne AI, Barth JF, et al (2013) Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus. J Virol 87(9):4952\u201364","journal-title":"J Virol"},{"issue":"10","key":"521_CR13","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1473-3099(15)00154-1","volume":"15","author":"A Huttner","year":"2015","unstructured":"Huttner A, Dayer J-A, Yerly S, et al (2015) The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomized double-blind, placebo-controlled phase 1\/2 trial. Lancet Infect Dis 15(10):1156\u201366","journal-title":"Lancet Infect Dis"},{"key":"521_CR14","doi-asserted-by":"crossref","first-page":"e02227","DOI":"10.1128\/mBio.02227-14","volume":"6","author":"JR Kugelman","year":"2015","unstructured":"Kugelman JR, Sanchez-Lockhart M, Andersen KG, et al (2015) Evaluation of the potential impact of Ebola virus genomic drift on the efficacy of sequence-based candidate therapeutics. MBio 6(1).pii:e02227","journal-title":"MBio"},{"issue":"8","key":"521_CR15","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s40262-015-0364-1","volume":"55","author":"V Madelain","year":"2016","unstructured":"Madelain V, Nguyen TH, Olivo A, et al (2016) Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials. Clin Pharmacokinet. 55(8):907\u201323.","journal-title":"Clin Pharmacokinet."},{"issue":"8","key":"521_CR16","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S1473-3099(04)01103-X","volume":"4","author":"S Mahanty","year":"2004","unstructured":"Mahanty S, Bray M (2004) Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis 4(8):487\u201398","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"521_CR17","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1080\/14760584.2016.1187566","volume":"15","author":"KA Martins","year":"2016","unstructured":"Martins KA, Jahrling PB, Bavari S, Kuhn JH (2016) Ebola virus disease candidate vaccines under evaluation in clinical trials. Expert Rev Vaccines 15(9):1101\u201312","journal-title":"Expert Rev Vaccines"},{"issue":"8","key":"521_CR18","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1172\/JCI81532","volume":"125","author":"M Meyer","year":"2015","unstructured":"Meyer M, Garron T, Lubaki NM, et al (2015) Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses. J Clin Invest 125(8):3241\u201355","journal-title":"J Clin Invest"},{"issue":"15","key":"521_CR19","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/jama.2016.4218","volume":"315","author":"ID Milligan","year":"2016","unstructured":"Milligan ID, Gibani MM, Sewell R, et al (2016) Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial. JAMA 315(15):1610\u201323","journal-title":"JAMA"},{"issue":"7549","key":"521_CR20","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nature14428","volume":"520","author":"CE Mire","year":"2015","unstructured":"Mire CE, Matassov D, Geisbert JB, et al (2015) Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus. Nature 520(7549):688\u201391","journal-title":"Nature"},{"key":"521_CR21","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.virusres.2015.10.021","volume":"211","author":"EI Ohimain","year":"2016","unstructured":"Ohimain EI (2016) Recent advances in the development of vaccines for Ebola virus disease. Virus Res 211:174\u201385","journal-title":"Virus Res"},{"key":"521_CR22","volume-title":"Maladie \u00e0 virus Ebola","author":"OMS","year":"2016","unstructured":"OMS (2016) Maladie \u00e0 virus Ebola. Aide m\u00e9moire N\u00b0103. (En ligne] (acc\u00e9d\u00e9 le 11 juin 2016)"},{"issue":"7","key":"521_CR23","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1128\/JVI.02864-12","volume":"87","author":"JS1 Richardson","year":"2013","unstructured":"Richardson JS1, Pillet S, Bello AJ, Kobinger GP (2013) Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates. J Virol 87(7):3668\u201377","journal-title":"J Virol"},{"issue":"5\u20136","key":"521_CR24","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1177\/2051013615611017","volume":"3","author":"S Sridhar","year":"2015","unstructured":"Sridhar S (2015) Clinical development of Ebola vaccines. Ther Adv Vaccines 3(5\u20136):125\u201338","journal-title":"Ther Adv Vaccines"},{"issue":"10","key":"521_CR25","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/nm.3702","volume":"20","author":"DA Stanley","year":"2014","unstructured":"Stanley DA, Honko AN, Asiedu C, et al (2014) Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med 20(10):1126\u20139","journal-title":"Nat Med"},{"issue":"6812","key":"521_CR26","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/35046108","volume":"408","author":"NJ Sullivan","year":"2000","unstructured":"Sullivan NJ, Sanchez A, Rollin PE, et al (2000) Development of a preventive vaccine for Ebola virus infection in primates. Nature 408(6812):605\u20139","journal-title":"Nature"},{"issue":"23","key":"521_CR27","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1016\/j.vaccine.2004.11.070","volume":"23","author":"DL Swenson","year":"2005","unstructured":"Swenson DL, Warfield KL, Negley DL, et al (2005) Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine 23(23):3033\u201342","journal-title":"Vaccine"},{"issue":"1","key":"521_CR28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1473-3099(15)00362-X","volume":"16","author":"MD Tapia","year":"2016","unstructured":"Tapia MD, Sow SO, Lyke KE, et al (2016) Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, doseescalation trial, and a nested, randomised, double-blind, placebocontrolled trial. Lancet Infect Dis 16(1):31\u201342","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"521_CR29","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1371\/journal.pntd.0001275","volume":"5","author":"Y Tsuda","year":"2011","unstructured":"Tsuda Y, Caposio P, Parkins CJ, et al (2011) A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus. PLoS Negl Trop Dis 5(8):e1275","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"521_CR30","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1586\/14760584.4.3.429","volume":"4","author":"KL Warfield","year":"2005","unstructured":"Warfield KL, Swenson DL, Demmin G, Bavari S (2005) Filovirus-like particles as vaccines and discovery tools. Expert Rev Vaccines 4(3):429\u201340","journal-title":"Expert Rev Vaccines"},{"issue":"S2","key":"521_CR31","doi-asserted-by":"crossref","first-page":"S430","DOI":"10.1086\/520583","volume":"196","author":"JL Warfield","year":"2007","unstructured":"Warfield JL, Swenson DL, Olinger GG, et al (2007) Ebola viruslike particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis 196(S2):S430\u20137","journal-title":"J Infect Dis"},{"issue":"9984","key":"521_CR32","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1016\/S0140-6736(15)60553-0","volume":"385","author":"FC Zhu","year":"2015","unstructured":"Zhu FC, Hou LH, Li JX, et al (2015) Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet 385(9984):2272\u20139","journal-title":"Lancet"}],"container-title":["Bulletin de la Soci\u00e9t\u00e9 de pathologie exotique"],"original-title":[],"language":"fr","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13149-016-0521-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13149-016-0521-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13149-016-0521-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T19:02:35Z","timestamp":1568401355000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13149-016-0521-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,19]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["521"],"URL":"https:\/\/doi.org\/10.1007\/s13149-016-0521-2","relation":{},"ISSN":["0037-9085","1961-9049"],"issn-type":[{"value":"0037-9085","type":"print"},{"value":"1961-9049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,19]]}}}